Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics


Centessa Pharmaceuticals Limited (CNTA): $5.17

0.30 (+6.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNTA Stock Price Chart Interactive Chart >

Price chart for CNTA

CNTA Price/Volume Stats

Current price $5.17 52-week high $25.98
Prev. close $4.87 52-week low $2.88
Day low $4.92 Volume 90,900
Day high $5.46 Avg. volume 236,265
50-day MA $5.61 Dividend yield N/A
200-day MA $10.14 Market Cap 486.19M

Centessa Pharmaceuticals Limited (CNTA) Company Bio


Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.


CNTA Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTA Latest Social Stream


Loading social stream, please wait...

View Full CNTA Social Stream

Latest CNTA News From Around the Web

Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial (“ACTION Study”) evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”). The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over

Yahoo | February 24, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares?

Every investor in Centessa Pharmaceuticals Limited ( NASDAQ:CNTA ) should be aware of the most powerful shareholder...

Yahoo | January 1, 2022

Checking In On Centessa Pharmaceuticals

No summary available.

Seeking Alpha | December 23, 2021

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $11.33

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) gapped up prior to trading on Tuesday . The stock had previously closed at $11.33, but opened at $11.82. Centessa Pharmaceuticals shares last traded at $12.03, with a volume of 1,219 shares changing hands. Separately, Zacks Investment Research raised Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and set […]

Transcript Daily | December 23, 2021

Read More 'CNTA' Stories Here

CNTA Price Returns

1-mo 59.08%
3-mo -43.06%
6-mo -55.39%
1-year -76.63%
3-year N/A
5-year N/A
YTD -54.09%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3919 seconds.